We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |


TORALD SOLLMANN, M.D.; HAROLD COLE, M.D.; KATHARINE HENDERSON, A.B.; George W. Binkley, M.D.; Harris Connors, M.D.; G. Cooper, M.D.; W. F. Schwartz, M.D.; Maurice Sullivan, M.D.; W. R. Love, M.D.
Arch Derm Syphilol. 1938;37(6):993-1002. doi:10.1001/archderm.1938.01480120059010.
Text Size: A A A
Published online

The oral absorption of ordinary bismuth compounds is too inconstant and too slight for reliable antisyphilitic action. Several special compounds have been introduced with claims that they have produced clinical and serologic benefit in syphilis. We have tried two of these, but found them clinically inactive and the excretion produced insignificant. Recently Hanzlik and his associates1 introduced a new type of compound, sobisminol (sodium bismuthate soluble), and reported it to be effective for oral as well as intramuscular administration and to produce a urinary excretion equal to that of the ordinary compounds for intramuscular injection. As we have developed a somewhat standardized technic for comparing the excretion produced by the various bismuth compounds, it appeared interesting to see how the excretion produced by this new compound, especially when administered orally, compared with that of the other compounds of which we have records and to attempt to attempt to correlate


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.